Studienlage · Detail
Klarer Nutzen
GRADE
Moderat
873 Zitate
Stichproben = 50.087 Pat.
DauerFollow-up 1969–70 bis…
KontrolleKein Cannabiskonsum
EndpunktKrankenhauseinweisung wg…
Verblindungn.a.
DesignHistorische Kohortenstudie
Kernaussage
Dosisabhängig erhöhtes Schizophrenie-Risiko bei Cannabiskonsum, nicht durch andere Drogen oder Persönlichkeitsmerkmale erklärbar.
Zusammenfassung
n=50.087 schwedische Wehrpflichtige (Kohorte 1969), Langzeit-Follow-up auf Schizophrenie-Hospitalisation. Dosisabhängige Risikoerhöhung: bereinigter OR für >50-maliger Konsum 6,7 (95% CI 2,1–21,7) in der Nur-Cannabis-Gruppe; OR-Trend für ansteigenden Gebrauch 1,2 (95% CI 1,1–1,4, p<0,001). Assoziation nach Kontrolle für andere Drogen und Persönlichkeitsmerkmale robust.
P
PopulationSchwedische Wehrpflichtige des Jahrgangs 1969 (>97% der männlichen Bevölkerung im Alter 18–20 Jahre), n=50.087
I
InterventionSelbst berichteter Cannabiskonsum (frequenzabhängig, inkl. Untergruppe ausschließlich Cannabis ohne andere Drogen)
C
KontrolleKein Cannabiskonsum (Referenzgruppe innerhalb der Kohorte)
O
OutcomeAdjustiertes OR für linearen Trend steigender Cannabisfrequenz: 1,2 (95%-KI 1,1–1,4, p<0,001); bei ausschließlichem Cannabiskonsum OR 1,3 (1,1–1,5, p=0,015); >50-maliger Konsum (Cannabis-only): OR 6,7 (2,1–21,7)
Vertrauen in die Evidenz
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Klarer Nutzen
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
<h4>Objectives</h4>An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address these uncertainties while extending the follow up period to identify additional cases.<h4>Design</h4>Historical cohort study.<h4>Setting</h4>1969-70 survey of Swedish conscripts (>97% of the country's male population aged 18-20).<h4>Participants</h4>50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics.<h4>Main outcome measures</h4>Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage.<h4>Results</h4>Cannabis was associated with an increased risk of developing schizophrenia in a dose dependent fashion both for subjects who had ever used cannabis (adjusted odds ratio for linear trend of increasing frequency 1.2, 95% confidence interval 1.1 to 1.4, P<0.001), and for subjects who had used only cannabis and no other drugs (adjusted odds ratio for linear trend 1.3, 1.1 to 1.5, P<0.015). The adjusted odds ratio for using cannabis >50 times was 6.7 (2.1 to 21.7) in the cannabis only group. Similar results were obtained when analysis was restricted to subjects developing schizophrenia after five years after conscription, to exclude prodromal cases.<h4>Conclusions</h4>Cannabis use is associated with an increased risk of developing schizophrenia, consistent with a causal relation. This association is not explained by use of other psychoactive drugs or personality traits relating to social integration.
„Was dem Handeln im Weg steht, wird zum Weg.“